Clinical Updates from ADP-A2M4CD8’s SURPASS Study; Adaptimmune to Evaluate Multiple Combinations in the SURPASS Program; Adaptimmune’s ESMO 2022 Investor Event
On Friday, September 9, Adaptimmune held their ESMO 2022 Investor Event (press release / presentation) highlighting the clinical results from ADP-A2M4CD8’s (next-gen MAGE-A4 SPEAR-T) Ph1 SURPASS trial presented at ESMO 2022. Moreover, management disclosed future plans for the SURPASS family of trials. Below, Celltelligence provides insights on ADP-A2M4CD8’s updated clinical results, while discussing Adaptimmune’s new strategy to combine ADP-A2M4CD8 with checkpoint inhibitors.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.